BioRestorative Aims to Disrupt Aesthetics with Regenerative Skincare at Be+Well Show
Event summary
- BioRestorative Therapies will participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026.
- The show attracts over 35,000 beauty and wellness professionals and 600 exhibiting brands.
- Crystal Romano, Head of Global Commercial Operations, will lead BioRestorative’s engagement.
- BioRestorative is leveraging its cell-based secretome technology to enter the aesthetics and longevity markets.
The big picture
BioRestorative is attempting to disrupt the $500+ billion global beauty and personal care market by applying regenerative medicine technology, a strategy that positions them against established brands with significant marketing budgets. Their focus on a vertically integrated, cGMP-compliant manufacturing process differentiates them, but also introduces operational complexity. The company’s success will depend on convincing practitioners and consumers that biologically active ingredients offer a superior, albeit premium, alternative to traditional cosmetic treatments.
What we're watching
- Market Adoption
- The success of BioRestorative’s strategy hinges on the continued adoption of exosome treatments and regenerative skincare by clinics and medspas, which may be influenced by evolving consumer preferences and clinical data.
- Regulatory Landscape
- The company’s ambition to pioneer FDA approvals in the biocosmeceuticals space will be heavily influenced by the FDA’s evolving regulatory framework for cell-based products and biologics, potentially creating hurdles or accelerating pathways.
- Manufacturing Scale
- BioRestorative’s vertically integrated manufacturing model, while providing a competitive advantage, will need to demonstrate scalability and cost-effectiveness to support broader commercialization and maintain premium pricing.
Related topics